TB alliance welcome US lowering cost of treatment as new research commences for failed or treatment-intolerant multidrug-resistant TB.
TB Alliance made this statement when they welcome TB Reach program that awarded $ 15.4 million by Wave 7 to support the 37 new research on finding new diagnostic and care systems for the multidrug resistant TB.
The researchers are going to focus on unmasking why the drug failed treatment in the severely hit countries. This is because TB remains an infectious disease and continues to account for millions of deaths worldwide and TB Alliance hopes that Belarus, South Africa, Tajikistan and Ukrain, with the highest cases of multidrug-resistant TB find a better cure.
“According to the STOP TB Partnership, four of these projects will focus on studying the use of a six-month, three-drug, all-oral treatment in countries that are confronting extensively drug-resistant tuberculosis (TB) and failed or treatment –intolerant multidrug –resistant TB: Belarus, South Africa, Tajikistan and Ukrain.These countries now have an opportunity to lead the way toward implementing new ways of treating highly drug- resistant forms of TB. We are greatly encouraged by this news and the hope it provides for patients in need,” stated TB Alliance.
TB Alliance while commenting on the WHO Global TB Report 2019 stated that multidrug –resistance is a puzzle that is mysterious because TB is preventable yet there’s just a 50% chances of cure using treatments and drains many people into poverty.
“The realities of treating drug-resistant TB today –often with 18+ months of treatment with thousands of pills and a success rate of 56%-continue to take a dire economic and human toll. Progress against TB has been limited to partial solutions and slow improvements. In the face of resistance to TB treatments ,with about half a million cases of drug-resistant TB last year, patients and their families are in desperate need of new solutions-including scientific innovation in drugs, diagnostics and vaccines,” stated TB Alliance.
TB Alliance called for bolder and accelerated work to speed up finding solutions which are available from the Global Fund but will be obtained with proof of work and this should be supplemented with more impactful treatment works.
PEPFAR already welcome the reduction of price for TB drug meant for prevention of TB that will ease the treatment of co-infection with HIV.
“PEPFAR is encouraged by today’s announcement by Unitaid, the Global Fund to Fight AIDS ,Tuberculosis and Malaria ,and global biopharmaceutical company Sanofi that reduces the price of rifapentine, an FDA-approved tuberculosis preventive treatment (TPT) ,to approximately $15 for a three-month treatment course .This price reduction makes a shorter ,safer, and affordable TPT regimen more available to low- and middle income countries with high burdens of tuberculosis (TB) and HIV,” stated PEPFAR.
PEPFAR will increase investment in TB/HIV co-infection treatment over the next two years because they know that ripaferen drug will only treat a fraction of co-infected people who need the drug.
Contact: Everlyne Otieno
Company: The Recover
Address: Huntington Beach, CA
Contact Number: (888) 510-3898